Triochem Product

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE331E01013
  • NSEID:
  • BSEID: 512101
INR
17.40
0.00 (0.00%)
BSENSE

Jun 11, 03:30 PM

BSE+NSE Vol: 0

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

0

Shareholding (Mar 2026)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

68.65%

Why is Triochem Products Ltd falling/rising?

12-Jun-2026

As of 11-Jun, Triochem Products Ltd's stock price remains unchanged at 17.40, reflecting a consistent 0.00% change over various periods. The stock has underperformed against the benchmark Sensex and is trading below its moving averages, indicating a bearish trend and lack of investor confidence.

As of 11-Jun, Triochem Products Ltd's stock price is currently at 17.40, with no change from the previous trading session. The stock has shown a consistent performance of 0.00% change over various periods, including 1 week, 1 month, year-to-date, and 1 year, indicating a lack of upward or downward movement in its price. <BR><BR>In comparison to the benchmark Sensex, which has declined by 0.71% over the past week and 2.87% over the past month, Triochem Products Ltd has also underperformed, particularly today, where it lagged behind its sector by a significant margin of 99.34%. Additionally, the stock has not traded on 5 out of the last 20 days, suggesting erratic trading behavior. <BR><BR>The stock is currently trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically indicates a bearish trend. Furthermore, while the BSE Small Cap index has gained by 1.42%, Triochem Products Ltd has not benefited from this upward movement, reflecting a lack of investor confidence or interest in the stock at this time. <BR><BR>Overall, the combination of stagnant price movement, underperformance against the sector, erratic trading activity, and trading below moving averages contributes to the perception that Triochem Products Ltd is currently in a falling trend.

View full answer

Which are the latest news on Triochem Product?

12-Jun-2026
No latest news for Triochem Product found.

What does Triochem Product do?

11-Jun-2026

Triochem Products Ltd manufactures and exports pharmaceutical products, APIs, and chemicals, operating as a Micro Cap company. As of March 2026, it reported a net profit of 8 Cr.

Overview: <BR>Triochem Products Ltd is engaged in the manufacturing and exporting of pharmaceutical products, APIs, and chemicals, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap company.<BR><BR>History: <BR>Triochem Products Ltd was incorporated on January 17, 1972. The latest quarterly results reported are for March 2026, during which the company reported its net profit.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 8 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR Cr (Micro Cap)<BR><BR>Key Metrics: <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 0.00% <BR>Price to Book: 0.00<BR><BR>Contact Details: <BR>Address: Sambhava Chambers, 4th Floor Sir P M Road Mumbai Maharashtra : 400001 <BR>Tel: 91-22-22663150 <BR>Email: investor@triochemproducts.com <BR>Website: http://www.triochemproducts.com

View full answer

Who are in the management team of Triochem Product?

11-Jun-2026

The management team of Triochem Product includes Ramu S Deora (CEO), Sunil S Jhunjhunwala (Independent Director), S S Sharma (Director), Girish Kumar Pungalia (Independent Director), Rajesh Ramu Deora (Director), Ureca Shirish Shirole (Company Secretary), and Grace R. Deora (Non-Executive Director).

The management team of Triochem Product includes the following individuals:<BR><BR>1. Ramu S Deora - Director & Chief Executive Officer<BR>2. Sunil S Jhunjhunwala - Independent Director<BR>3. S S Sharma - Director<BR>4. Girish Kumar Pungalia - Independent Director<BR>5. Rajesh Ramu Deora - Director<BR>6. Ureca Shirish Shirole - Company Secretary & Compliance Officer<BR>7. Grace R. Deora - Non-Executive Director<BR><BR>If you have any more questions about the company or its management, feel free to ask!

View full answer

Who are the peers of the Triochem Product?

11-Jun-2026

Triochem Product's peers include Beryl Drugs, Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, Shyama Computro., Fabino Enter, and Saroja Pharma In. Most peers exhibit below-average management risk and growth, with Beryl Drugs showing the highest 1-year return at 31.73% and Vivanza Biosci. the lowest at -29.75%.

Peers: The peers of Triochem Product are Beryl Drugs, Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, Shyama Computro., Fabino Enter, and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Beryl Drugs, Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Fabino Enter, while Average management risk is found at Unjha Formul. and Saroja Pharma In. Shyama Computro. does not qualify for management risk assessment. Growth is Below Average for Beryl Drugs, Decipher Labs, Brawn Biotech, Vivanza Biosci., and Fabino Enter, while Average growth is noted at Ganga Pharma. Unjha Formul. has Below Average growth, and Saroja Pharma In has Below Average growth as well. Shyama Computro. does not qualify for growth assessment. Capital Structure is rated as Good for Unjha Formul., Average for Ganga Pharma., and Below Average for Beryl Drugs, Decipher Labs, Vivanza Biosci., Brawn Biotech, Fabino Enter, and Saroja Pharma In, with Shyama Computro. not qualifying.<BR><BR>Return Snapshot: Beryl Drugs has the highest 1-year return at 31.73%, while Vivanza Biosci. has the lowest at -29.75%. Triochem Product's 1-year return is 0.00%, which is lower than Beryl Drugs and higher than Vivanza Biosci. Additionally, the six-month return is negative for Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Fabino Enter.

View full answer

Who are the top shareholders of the Triochem Product?

17-Jul-2025

The top shareholders of Triochem Product include Rajesh Ramu Deora with 14.69%, Ambernath Plasto Packaging Private Limited at 4.9%, and individual investors holding a combined 15.53%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of Triochem Product include the promoters, with Rajesh Ramu Deora holding the largest share at 14.69%. Additionally, Ambernath Plasto Packaging Private Limited is the highest public shareholder, owning 4.9%. Individual investors collectively hold 15.53% of the shares. There are currently no mutual funds or foreign institutional investors holding shares in the company.

View full answer

When is the next results date for Triochem Product?

16-May-2025

No Upcoming Board Meetings

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR Cr (Micro Cap)

stock-summary
P/E

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.00

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2026)
Net Profit:
8 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Icon
Company does not have enough history
Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Newspaper Publication

01-Jun-2026 | Source : BSE

Audited Financial Result for the quarter and year ended 31st March 2026 in newspaper

Non-Applicability Of Statement Of Deviation Or Variation Under Regulation 32(1) Of The SEBI (Listing Obligation & Disclosures Requirement) Regulation 2015 For The Quarter Ended 31St March 2026.

29-May-2026 | Source : BSE

We hereby confirm that the Company has not raised / made offers by way of Public Issue Rigth Issue Preferential Issure Qualified Institutions Placement (QIP) etc. therefore for the quarter ended on 31st March 2026 is not applicable to our Company

Submission Of Audited Financial Results For The Quarter And Year Ended 31St March 2026

29-May-2026 | Source : BSE

Audited Financial Results of the Company for the Quarter / Year Ended 31st March 2026 duly Reviewed by the Audi Committee along with Declaration is given in compliance to Regulation 30(3)(d) of the SEBI (LODR) Regulation 2015...

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

No Data Found

Valuation key factors

No Data Found

Technicals key factors

Indicator
Weekly
Monthly
Icon
Technical indicator has not been calculated since the stock has been active for a short period
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Rajesh Ramu Deora (14.69%)

Highest Public shareholder

Triochem Laboratories Private Limited (4.9%)

Individual Investors Holdings

15.53%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Dec 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 6,507.69% vs 31.58% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.22",
          "val2": "-0.38",
          "chgp": "42.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.08",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "11.17",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "8.33",
          "val2": "-0.13",
          "chgp": "6,507.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -83.33% vs 89.38% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.78",
          "val2": "-0.60",
          "chgp": "-30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.22",
          "val2": "-0.12",
          "chgp": "-83.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -1,066.67% vs 97.74% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.16",
          "val2": "-1.19",
          "chgp": "2.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.35",
          "val2": "-0.03",
          "chgp": "-1,066.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 2,092.50% vs 60.40% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.38",
          "val2": "-1.22",
          "chgp": "-13.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.08",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "11.17",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.97",
          "val2": "-0.40",
          "chgp": "2,092.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.22
-0.38
42.11%
Interest
0.08
0.00
Exceptional Items
11.17
0.00
Standalone Net Profit
8.33
-0.13
6,507.69%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Net Sales

QoQ Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Dec 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 6,507.69% vs 31.58% in Dec 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.78
-0.60
-30.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.22
-0.12
-83.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Net Sales

Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is -83.33% vs 89.38% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.16
-1.19
2.52%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.35
-0.03
-1,066.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Net Sales

YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -1,066.67% vs 97.74% in Dec 2024

Annual Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.38
-1.22
-13.11%
Interest
0.08
0.00
Exceptional Items
11.17
0.00
Standalone Net Profit
7.97
-0.40
2,092.50%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Net Sales

YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2026 is 2,092.50% vs 60.40% in Mar 2025

stock-summaryCompany CV
About Triochem Products Ltd stock-summary
stock-summary
Triochem Products Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Triochem Products Ltd was incorporated in the year January 17, 1972. The Company is engaged in the business of manufacturer and exporter of pharmaceuticals products, API and chemicals.
Company Coordinates stock-summary
Company Details
Sambhava Chambers, 4th Floor Sir P M Road Mumbai Maharashtra : 400001
stock-summary
Tel: 91-22-22663150
stock-summary
investor@triochemproducts.com
Registrar Details
Sharex (India) Pvt Ltd , Unit No.1, Luthra Ind.Premises Andheri Kurla Road, Safed Pool , Mumbai